Early cancer drug trial halted after testing in 40 patients
NCT ID NCT05707676
Summary
This was an early safety study testing a new drug called LB4330 in patients with advanced solid tumors that had stopped responding to standard treatments. The trial aimed to find the safest dose and see how the drug behaves in the body. It was terminated early and enrolled 40 participants with various cancers, including stomach and pancreatic cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200120, China
Conditions
Explore the condition pages connected to this study.